Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,471.00    11.00 (0.75%)
Bid:
1,475.00
Ask:
1,477.00
Spread: 2.00 (0.136%)
Market Cap: £3.13b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Announcement

28 Nov 2017 10:24

RNS Number : 7220X
Hikma Pharmaceuticals Plc
28 November 2017
 

Stock Exchange Announcement

 

 

For immediate release

28th November 2017

 

 

 

 

Hikma Pharmaceuticals Public Limited Company 

(the "Issuer")

 

Re: Additional Guarantors of U.S.$500,000,000 4.250 per cent. Guaranteed Notes due 2020

(ISIN: XS1213834978)

(the "Notes")

guaranteed by each of

Arab Pharmaceutical Manufacturing PSC

Eurohealth (USA), Inc.

Hikma Farmacêutica (Portugal) S.A.

Hikma Pharmaceuticals LLC and

West-Ward Pharmaceutical Corp.

(the "Initial Guarantors")

 

The Issuer refers to (i) the terms and conditions of the Notes (the "Conditions") set out in the prospectus dated 8 April 2015 relating to the Notes and (ii) a deed of guarantee dated 10 April 2015 between the Issuer and the Initial Guarantors in favour of the Holders and the Relevant Account Holders (each as defined therein) (the "Deed of Guarantee").

 

Capitalised terms used in this Notice and not defined herein shall have the meanings as set out in the Conditions and the Deed of Guarantee.

 

 

NOTICE IS HEREBY GIVEN that, pursuant to and in compliance with the provisions of Condition 5.7 (Guarantor Group) and the Deed of Guarantee:

 

a) as of 21 August 2017, West-Ward Pharmaceuticals International Limited has, pursuant to an accession deed of guarantee dated 21 August 2017 and an accession deed of covenant dated 21 August 2017, become a Guarantor;

b) as of 29 April 2016, Roxane Laboratories, Inc. has, pursuant to an accession deed of guarantee dated 29 April 2016 and an accession deed of covenant dated 29 April 2016, become a Guarantor; and

c) as of 29 April 2016, West-Ward Columbus Inc. has, pursuant to an accession deed of guarantee dated 29 April 2016 and an accession deed of covenant dated 29 April 2016, become a Guarantor.

 

West-Ward Pharmaceuticals International Limited, Roxane Laboratories, Inc. and West-Ward Columbus Inc. are together "the Additional Guarantors".

 

Each Additional Guarantor has agreed to:

 

a) perform and observe all obligations expressed to be undertaken by a Guarantor under the Conditions, the Deed of Guarantee, a deed of covenant between the Issuer and the Initial Guarantors dated 10 April 2015 (the "Deed of Covenant") and a fiscal agency agreement between, among others, the Issuer, the Initial Guarantors and Citibank, N.A., London Branch dated 10 April 2015 (the "Fiscal Agency Agreement"), and each agrees that it shall be bound by the Conditions, the Deed of Guarantee, the Deed of Covenant and the Fiscal Agency Agreement in all respect as if it had been an original party thereto; and

 

b) jointly and severally with all the Initial Guarantors, unconditionally and irrevocably guarantee the payment of all sums expressed to be payable by the Issuer in respect of the Notes to the Holders and the Relevant Account Holders.

 

 

The following is the relevant information for the Additional Guarantors:

 

Registered name:

West-Ward Pharmaceuticals International Limited

Place of incorporation:

England and Wales

Date of incorporation:

23rd June 2011

Registered number:

07680243

Registered address:

1 New Burlington Place, London, W1S 2HR

Ownership:

The Additional Guarantor is a wholly owned subsidiary of the Issuer.

 

Registered name:

West-Ward Columbus Inc.

Place of incorporation:

Registered in the state of Delaware

Date of incorporation:

27th November 1978

Registered number:

863458

Registered address:

1809 Wilson RoadColumbusOH 43228United States

Ownership:

The Additional Guarantor is a wholly owned subsidiary of the Issuer.

 

Registered name:

Roxane Laboratories, Inc.

Place of incorporation:

Registered in the state of Nevada

Date of incorporation:

14 February 2005

Registered number:

E0034412005-8

Registered address:

1809 Wilson RoadColumbus

OH 43228United States

Ownership:

The Additional Guarantor is a wholly owned subsidiary of the Issuer.

 

 

Enquiries:

 

For enquiries or further information please contact:

Peter Speirs

Company Secretary

Hikma Pharmaceuticals PLC

E-mail: peter@hikma.uk.com

 

 

 

This announcement has been issued through the Companies Announcement Service of

The Irish Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEOKFDDKBDDCDB
Date   Source Headline
2nd Jun 202612:42 pmRNSDirector/PDMR Shareholding
1st Jun 20264:16 pmRNSTotal Voting Rights
1st Jun 202612:11 pmRNSTransaction in Own Shares
27th May 202610:05 amRNSTransaction in Own Shares
26th May 202610:30 amRNSTransaction in Own Shares
18th May 202610:55 amRNSTransaction in Own Shares
15th May 20269:45 amRNSChange of Registered Office
11th May 20261:10 pmRNSTransaction in Own Shares
6th May 20263:08 pmRNSDirector/PDMR Shareholding
5th May 20269:55 amRNSTransaction in Own Shares
1st May 202610:36 amRNSTotal Voting Rights
28th Apr 20261:29 pmRNSDirector/PDMR Shareholding
27th Apr 202611:55 amRNSTransaction in Own Shares
23rd Apr 20263:42 pmRNSResult of AGM
23rd Apr 20267:00 amRNSTrading Statement
20th Apr 202610:55 amRNSTransaction in Own Shares
13th Apr 20263:29 pmRNSDirector/PDMR Shareholding
13th Apr 202611:10 amRNSTransaction in Own Shares
9th Apr 20264:43 pmRNSDirector/PDMR Shareholding
7th Apr 20269:42 amRNSTransaction in Own Shares
1st Apr 202611:11 amRNSTotal Voting Rights
30th Mar 202610:55 amRNSTransaction in Own Shares
23rd Mar 202611:00 amRNSTransaction in Own Shares
18th Mar 202610:10 amRNSAnnual Financial Report and Notice of AGM
16th Mar 20269:29 amRNSTransaction in Own Shares
16th Mar 20269:29 amRNSTransaction in Own Shares
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:56 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLaunch of Buyback Programme
26th Feb 20267:00 amRNSFinal Results, Share Buyback & Leadership Changes
4th Feb 20265:29 pmRNSStatement regarding Hikma Pharmaceuticals Plc
3rd Feb 20267:00 amRNSNotice of Results
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
15th Dec 20253:59 pmRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSHikma announces CEO change and Board appointment
11th Nov 202512:13 pmRNSHolding(s) in Company
11th Nov 202511:42 amRNSDirector/PDMR Shareholding
7th Nov 202512:56 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSNovember Trading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.